Objective : Metabolic syndrome diseases, MSD (Hypertension, Adiposity, Diabetes mellitus and Dyslipidemia) are interrelated diseases with very high morbidity and mortality rates, thus requiring the search for new and effective treatment options. Aim of research was to investigate the clinical effectiveness of Liraglutide, a Glucagon-like peptide-1 receptor agonist [GLP-1 RA] in patients with MSD.
Methods : 100 patients (51 females and 49 males) were studied for 3 months. All patients had Essential Hypertension [EH] degree 1-2, stage II; Adiposity (BMI from 30.0–39.9 kg/m2); Diabetes mellitus type 2 [DM2] and Dyslipidemia; average age (60.6±5.2) years. All patients were divided into two groups: 47 patients treated with Metformin 1500mg/day, Diabeton® MR 60mg/day, Ramipril 5-10mg/day and Rosuvastatin 20mg/day constituted Group I [GI]; 53 patients treated with Metformin 1500mg/day, Diabeton® MR 60mg/day, Ramipril 5-10mg/day, Rosuvastatin 20mg/day and Liraglutide (Victoza®) 1.2mg/day constituted Group II [GII]. Groups were randomized based on age, sex, BMI and duration of MSD. 25 healthy volunteers constituted control group. Gen. clinical exam, BP, BMI, HbA1C, total cholesterol [TC], triglycerides [TG], LDL, HDL tests were conducted in all patients. Research was conducted with strict adherence to the Helsinki Declaration.
Results : HbA1C in GII was decreased to (6.80±0.60)% vs. (9.68±0.52)% before treatment (р<0.05) and in GI to (8.92±0.66)% vs. (9.45±0.65)% before treatment (р<0.05). In GI, TC was 6.67±0.43mmol/L (p<0.05) and exceeded that of GII by up to 18.68% (p<0.05). TG in GI was 2.68±0.21mmol/L (p<0.05) and was increased by up to 20.17% when compared with GII (p<0.05). LDL in GI was 3.85±0.29mmol/L and was higher than GII by up to 22.61% (p<0.05). HDL in GI amounted to 1.13±0.08mmol/L (p<0.05) and was lower, compared to its value in GII by up to 13.7% (p<0.05).
Discussion : After 3 months, BP in all GII patients did not exceed 145/95mmHg. This was not observed in GI patients. Average BMI reduced to 2 (p30.0kg/m2 (p<0.05) in GI.
Conclusion : GLP-1 RAs e.g. Liraglutide increases the clinical effectiveness of complex treatment in patients with MSD.
Aloysius Ikwuka– Specialist Medical Doctor in Internal Medicine, Dept. of Internal Medicine, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, Ivano-frankivsk, Ivano-Frankivs'ka Oblast', Ukraine
Specialist Medical Doctor in Internal Medicine
Dept. of Internal Medicine, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
Ivano-frankivsk, Ivano-Frankivs'ka Oblast', Ukraine
Though open to new opportunities, I am a highly dynamic, motivated teacher and fast-learner. I am endowed with excellent oral and written communication skills, and a very strong passionate commitment to the education of future healthcare professionals. I have more than 5 years of experience in teaching international students from 6 different continents and more than 56 different countries. I have published over 15 quality, original clinical research works in different reputable international journals.
I have course certificates from universities in 6 different continents, including the prestigious Ivy League universities like Harvard, Yale, Oxford etc. I am a member of American College of Physicians (ACP), American Association of Clinical Endocrinologists (AACE), Royal College of Physicians (RCP) London, and Nigerian Medical Association (NMA).